AmberGen announces that Dr. Michael Easterling, PhD will join Board of Directors

AmberGen announces that Dr. Michael Easterling, PhD, Director of Imaging for Bruker’s Life Science Mass Spectrometry Division, will join the company’s Board of Directors.

AmberGen Announces New Appointments for John Gillespie & Dr. Kenneth J. Rothschild

The Board of Directors has appointed John Gillespie as President and CEO of AmberGen.  Dr. Kenneth J. Rothschild, Founder and longtime CEO will become Executive Chairman and accept the newly created position of Chief Innovation Officer.

AmberGen and Bruker Collaborate on Spatial Biology Imaging Reagents for MALDI-Immunohistochemistry (MALDI-IHC)

Transforming Multiomics Spatial Tissue Biology with the Power of MALDI Mass Spectrometry for Imaging Targeted Proteins, Lipids, Glycans and Metabolites

PRESS RELEASE

WATERTOWN, Massachusetts, April 08, 2022 – Boston-area life science technology company AmberGen Inc. today announced that it has closed a strategic investment by Bruker Corporation, one of the world’s leading scientific instrumentation and life-science solutions companies. AmberGen’s innovative and proprietary Miralys® Spatial Biology Imaging Reagents for MALDI based Immunohistochemistry (MALDI-IHC), are currently in Beta release.

Transforming Multiomic Spatial Tissue Imaging with MALDI Mass Spectrometry.

Combined with Bruker’s unique ultra-high speed (10 kHz), high-spatial resolution (5 µm) MALDI imaging mass spectrometers, such as Bruker’s rapifleX® and timsTOF fleX™ systems, the new Miralys workflows produce tissue images of targeted protein biomarkers in both fresh frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples.  AmberGen’s unique peptide code photocleavable mass tag (PCMT) technology enables high-plex MALDI-MS imaging to detect high-plex panels (up to approximately 100 plex) of targeted proteins across tissue sections with a variable, large field of view (up to 25 mm by 75 mm), suitable for tissue and pathology research.  MALDI-IHC workflows are uniquely multiomic in the sense that they are capable of imaging small molecule drugs, their metabolites, glycans, and lipids, in addition to IHC-targeted protein biomarkers.  This is done all on the same tissue slide with a larger field of view than many other mass cytometry imaging approaches.

Miralys reagents make MALDI-IHC both multiomic and multimodal since its optional dual-labeled reagents enable spatial co-registration of multiple imaging modalities, including those based on mass spectrometry, immunofluorescence imaging for up to 5 probes, and bright-field microscopy.  Miralys MALDI-IHC workflows are not applicable for sub-cellular or small single-cell imaging, nor for DNA, methylation or mRNA imaging, and therefore, complement other spatial transcriptomics microscopy methods.

Dr. Michael Easterling, Director of Imaging for Bruker’s Life Science Mass-Spectrometry Division, stated: “The MALDI-MS tissue imaging community has long expressed a desire to spatially map targeted proteins, together with glycans, lipids, drugs, and their metabolites, where MALDI has found widespread utility using a label-free approach.  The innovative photocleavable peptide code mass tag technology developed by AmberGen for labelling proteins of interest is a perfect combination for large field-of-view, multiomic and multimodal spatial tissue biology applications.  This additional information will be fundamentally important for oncology and immuno-oncology research, and pathology research.”

Dr. Kenneth Rothschild, Founder and Executive Chairman of AmberGen, Inc., commented: “The Miralys® MALDI-IHC platform provides the life sciences market with very high multiplexed, multiomic, and multimodal imaging capabilities for understanding the complex mechanisms of disease and response to pharmaceutical treatment.  This strategic investment by Bruker will accelerate the introduction of the Miralys spatial biology approach to a wide variety of researchers and catalyze progress in critical areas such as tissue pathology research and drug development. We are confident that this is the beginning of a new generation of spatial tissue imaging with integrated multiomics capabilities.”

Dr. Mark Lim, Executive VP and CSO of AmberGen, noted that “The key to the superior performance of our Miralys reagents stems from our innovative mass-tags which offer fast and efficient photocleavage and robust probe labeling as well as optimized work-flows for high-plex multiomic imaging.”

About AmberGen Inc. – http://www.AmberGen.com

AmberGen, Inc. is a privately held, Boston-area company founded in 1995 to commercialize pioneering photonic technology developed at Boston University’s Molecular Biophysics Laboratory and the Photonics Center. AmberGen’s development of proprietary peptide code photocleavable linkers (PC-Linker™) led to the early introduction of novel photocleavable reagents, such as PC-Biotin and PC-Phosphoramidites which underlie several major commercial proteomic and genomic technologies. The company’s mission is to innovate in the area of therapeutics and diagnostics by solving key problems that limit progress in medicine. AmberGen’s approach combines patented techniques in proteomics and light-based control of biomolecules.

Media Contacts:

For AmberGen, John Gillespie, CEO, AmberGen Inc., Email info@AmberGen.com

 

Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session

Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session at US HUPO (Charleston, SC), where he gave a presentation describing AmberGen’s Miralys™ MALDI-IHC technology.

The paper “Highly Multiplexed Immunohistochemical MALDI-MS Imaging of Biomarkers in Tissues” was published in The Journal of the American Society for Mass Spectrometry

The paper “Highly Multiplexed Immunohistochemical MALDI-MS Imaging of Biomarkers in Tissues” with co-authors Gargey Yagnik PhD., Ziying Liu MD, Kenneth J. Rothschild, PhD., and Mark J. Lim PhD. of AmberGen was published in The Journal of the American Society for Mass Spectrometry.   The article describes the new Miralys™ photocleavable mass-tags and MALDI-IHC tissue imaging technology (https://pubs.acs.org/doi/10.1021/jasms.0c00473).  As of April 2022 the article was the 3rd “most read” paper in this prestigious journal over the preceding 12 month period.

Dr. Mark Lim of AmberGen gave an invited presentation sponsored by Bruker at the European Association for Cancer Research (EACR)

Dr. Mark Lim of AmberGen was honored to be an invited keynote speaker at the “Innovation in Mass Spectrometry Imaging Omics” Session at US HUPO (Charleston, SC), where he gave a presentation describing AmberGen’s Miralys™ MALDI-IHC technology.

Dr. Mark Lim Presentation at Bruker’s “Virtual eXceed Symposia and Breakfast Workshops: Expanding the Horizons of Singe Cell Research” during ASMS 2021 in Philadelphia.

Dr. Mark Lim had the opportunity to give a presentation at Bruker’s “Virtual eXceed Symposia and Breakfast Workshops: Expanding the Horizons of Singe Cell Research” during ASMS 2021 in Philadelphia.

AmberGen awarded a $2.5 million, 2-year Phase II SBIR grant from NIH-NIA

AmberGen awarded a $2.5 million, 2-year Phase II SBIR grant from NIH-NIA to develop a blood-based Alzheimer Diagnostic Assay based on its proprietary PC-PURE technology

Dr. Gargey Yagnik, PhD is appointed as Director of Mass Spectrometry

Dr. Gargey Yagnik, PhD is appointed as Director of Mass Spectrometry.

AmberGen receives US Patent 10,088,474 for its pioneering PC-PURE technology for multiplex Allergy diagnostics

AmberGen receives US Patent 10,088,474 for its pioneering PC-PURE technology for multiplex Allergy diagnostics.